The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors

The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors

Background: Despite having revolutionized the treatment paradigm for advanced melanoma, not all patients benefit from immune checkpoint inhibitor therapy. To date, there are no predictive biomarkers for response or the occurrence of immune-related adverse events (irAEs) to programmed cell death prot...

Bibliográfalaš dieđut
Váldodahkkit:	A. Boutros, R. Carosio, D. Campanella, F. Spagnolo, B. Banelli, A. Morabito, M.P. Pistillo, E. Croce, F. Cecchi, P. Pronzato, P. Queirolo, E. Raposio, V. Fontana, E.T. Tanda
Materiálatiipa:	Artihkal
Giella:	English
Almmustuhtton:	Elsevier 2023-12-01
Ráidu:	Immuno-Oncology and Technology
Fáttát:	melanoma SNV single nucleotide gene variant PD-1 PD-L1
Liŋkkat:	http://www.sciencedirect.com/science/article/pii/S2590018823000369

Geahča maid

Peptide Blockers of PD-1-PD-L1 Interaction Reinvigorate PD-1-Suppressed T Cells and Curb Tumor Growth in Mice
Dahkki: Shanshan (Jenny) Zhong, et al.
Almmustuhtton: (2024-07-01)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
Dahkki: Olga Yajuk, et al.
Almmustuhtton: (2021-06-01)

Activity of Negative Regulation of the PD-1/PD-L1/PD-L2 T-Cell Response System in Patients with Pneumonia and Inﬂuenza A (H1N1)
Dahkki: A. V. Malyarchikov, et al.
Almmustuhtton: (2021-08-01)

Meta-analysis of the correlation between glioma prognosis and PD-1/PD-L1 expression
Dahkki: Chang-cheng Ren, et al.
Almmustuhtton: (2023-12-01)

High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood
Dahkki: Kimberly Krueger, et al.
Almmustuhtton: (2022-09-01)

PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
Dahkki: Xiaohui Ren, et al.
Almmustuhtton: (2024-04-01)

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
Dahkki: Sara Zalba, et al.
Almmustuhtton: (2020-06-01)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
Dahkki: Yongshuai Jiang, et al.
Almmustuhtton: (2019-05-01)

Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood
Dahkki: Kimberly Krueger, et al.
Almmustuhtton: (2022-10-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
Dahkki: Kazuhiko Hashimoto, et al.
Almmustuhtton: (2020-07-01)

PD-L1/PD-1 pathway: a potential neuroimmune target for pain relief
Dahkki: Daling Deng, et al.
Almmustuhtton: (2024-04-01)

Regulatory mechanisms of PD-1/PD-L1 in cancers
Dahkki: Xin Lin, et al.
Almmustuhtton: (2024-05-01)

Association of PD-1 and PD-L1 protein expression with selected clinical and morphological parameters in colorectal cancers
Dahkki: Paulina Poter, et al.
Almmustuhtton: (2024-05-01)

نقش PD-1/ PD-L1 و Anti-PD-1/ PD-L1 در پیشرفت و سرکوب سرطان
Dahkki: نرگس عبدالهی, et al.
Almmustuhtton: (2023-11-01)

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy
Dahkki: Hongbo Zhang, et al.
Almmustuhtton: (2021-06-01)

Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
Dahkki: Peng Ding, et al.
Almmustuhtton: (2023-05-01)

Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer
Dahkki: Faisal K. Alkholifi, et al.
Almmustuhtton: (2022-11-01)

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways
Dahkki: Rong Wang, et al.
Almmustuhtton: (2024-04-01)

Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors
Dahkki: GAN Zi-ying, TANG Hui
Almmustuhtton: (2022-04-01)

Research progress and challenges of the PD-1/PD-L1 axis in gliomas
Dahkki: Dong Jiacheng, et al.
Almmustuhtton: (2024-09-01)

Efficacy of PD-1 or PD-L1 inhibitors for the therapy of cervical cancer with varying PD-L1 expression levels: a single-arm meta-analysis
Dahkki: Jie Yang, et al.
Almmustuhtton: (2024-08-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
Dahkki: Ruiting Li, et al.
Almmustuhtton: (2021-06-01)

Novel nanotherapeutics for cancer immunotherapy by albumin nanoparticles functionalized with PD-1 and PD-L1 aptamers
Dahkki: Qiping Jiang, et al.
Almmustuhtton: (2024-01-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
Dahkki: Tianrui Yang, et al.
Almmustuhtton: (2021-02-01)

IMMUNE RESISTANCE VIA A PD-1/PD-L1 MECHANISM IN GLIOBLASTOMA
Dahkki: V.S. KUSHNIROVA, et al.
Almmustuhtton: (2023-12-01)

Companion diagnostics and predictive biomarkers for PD-1/PD-L1 immune checkpoint inhibitors therapy in malignant melanoma
Dahkki: Zeping Wang, et al.
Almmustuhtton: (2024-10-01)

Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities
Dahkki: Melinda Badenhorst, et al.
Almmustuhtton: (2024-06-01)

Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis
Dahkki: Fabian Krutzek, et al.
Almmustuhtton: (2022-06-01)

Virtual Screening and In Vitro Evaluation of PD-L1 Dimer Stabilizers for Uncoupling PD-1/PD-L1 Interaction from Natural Products
Dahkki: Jrhau Lung, et al.
Almmustuhtton: (2020-11-01)

An extension of cancer immunotherapy with dostarlimab, the PD1-PD L1 pathway blocker
Dahkki: Sitangshu Sekhar Biswas, et al.
Almmustuhtton: (2023-12-01)

Status of PD-1 and PD-L1 expression in invasive urothelial carcinoma of the bladder with mismatch repair protein deficiency
Dahkki: Nuran Sungu, et al.
Almmustuhtton: (2023-10-01)

Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC)
Dahkki: Joanna Bialek, et al.
Almmustuhtton: (2022-12-01)

PD-1 gene polymorphisms and thyroid expression of PD-1 ligands differ between Graves’ and Hashimoto’s diseases
Dahkki: Mayumi Kawabata, et al.
Almmustuhtton: (2021-10-01)

Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance
Dahkki: Ugochi Ebinama, et al.
Almmustuhtton: (2023-11-01)

Refining PD-1/PD-L1 assessment for biomarker-guided immunotherapy: A review
Dahkki: Marek Zdrenka, et al.
Almmustuhtton: (2024-01-01)

Progress of research on PD-1/PD-L1 in leukemia
Dahkki: Huizhen Cao, et al.
Almmustuhtton: (2023-09-01)

Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era
Dahkki: SHAN Baoen
Almmustuhtton: (2023-09-01)

Visualization of PD-L1-positive and PD-1-positive immune cell contact in the breast cancer microenvironment
Dahkki: A. Yu. Kalinchuk, et al.
Almmustuhtton: (2024-03-01)

PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas
Dahkki: Wei Xie, et al.
Almmustuhtton: (2022-07-01)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
Dahkki: Edyta Zyla, et al.
Almmustuhtton: (2021-08-01)